20 ( )2017 57 5JournalofNanchangUniversity(MedicalSciences)2017,Vol.57No.5 ApoE,, (, 330006) : (,CHD) E(ApoE) 401CHD(CHD ) (TC) (TG) (LDL) (HDL) A1(ApoA1) B(ApoB) a (LPa), CHD (60 )ApoE CHD 6, E2/E2 E3/E3 E4/E4 E3/E4 E2/E3 E2/E4, E3/E3 E3/E4 E2/E3 E2/E4,,CHD e4 (P<0.05);CHD,E3/E3,E2/E2 TC Lpa,HDL ApoA,E4/E4 TC LDL Lpa (P<0.05) ApoE,e4 CHD : ; ; : R541.4 : A : 2095-4727 (2017)05-0020-03 DOI:10.13764/j.cnki.ncdm.2017.05.005 RelationshipbetweenApoEGenePolymorphismandLipid SpectruminPatientswithCoronaryHeartDisease LVXiao-lin,WANLa-gen,LIUShu-yuan (ClinicalLaboratory,the FirstAffiliated Hospitalof Nanchang University,Nanchang330006,China) ABSTRACT:Objective TostudytherelationshipbetweenapolipoproteinE(ApoE)genepoly- morphismandserumlipidlevelsinpatientswithcoronaryheartdisease(chd).methods Levels oftotalcholesterol(tc),glycerin(tg),low densitylipoproteincholesterol(ldl),highdensity lipoproteincholesterol(hdl),apolipoproteina1(apoa1),apolipoproteinb(apob)andlipopro- teina(lpa)weredetectedusingbiochemicalmethodsin401patients with CHD.Inaddition, ApoEgenepolymorphism wasmeasuredusinggene-chipmethodinchdpatientsand60healthy controls.results Sixgenotypes(E2/E2,E3/E3,E4/E4,E3/E4,E2/E3,E2/E4)werefoundin CHDgroup,and4genotypes(E3/E3,E3/E4,E2/E3,E2/E4)incontrolgroup.Compared with controlgroup,thefrequencyofe4increasedinchdgroup(p<0.05).comparedwithchdpa- tientswithe3/e3genotype,levelsoftcandlpadecreasedandlevelsof HDLand ApoAin- creasedinpatientswith E2/E2genotype,andlevelsofTC,LDLandLpaincreasedinpatients withe4/e4genotype(p<0.05).conclusion ApoEgenepolymorphismiscloselyrelatedtolipid metabolism.thee4genemaybeoneoftheimportantgeneticfactorsforchd. KEY WORDS:apolipoprotein;genepolymorphism;coronaryheartdisease;serumlipid (,CHD), :2017-06-02 : (1972 ),,,,
: ApoE 21, 1.4 DNA,CHD [1-2] (MRFIT) 6 1.5 PCR [3], CHD E(ApoE), (CM) 30s 65 45s (VLDL) β-vldl,apoe, ApoE :50 2min,95 15min;94 45 ; 1.6 DNA ;PCR, : [4] [5-6] ApoE ApoE 1.7 CHD, 7150 (TC): ; 401CHD ApoE, (TG):, ;, ApoE (LDL): ; CHD 1 1.1 1.8 20157 12 x±s, ; CHD 401 (CHD ),, 278,123 1981 χ 2,P<0.05 SPEE17.0 60 ( ), 2 CHD, 33,27 1.2 5 ml, EDTA 2.1 ApoE CHD ApoE (2 ml), DNA DNA; 1 1,401CHD 6 (3mL), 1.3 ABI2720PCR, (Sinochips- Megan DNA DNA, 5μLDNA PCR, 4,, (HDL): ; A1(ApoA1): ; B(ApoB): ; a(lpa):,e3/e3,e3 83. 5%; 4, E2/E2 E4/E4,E3/E3 e3 ;,CHD PGA),, 7150 e4 (P<0.05) 1 CHD ApoE %(n) E n E2/E2 E2/E3 E3/E3 E3/E4 E2/E4 E4/E4 e2 e3 e4 CHD 401 0.7(3) 13.7(55)69.3(278) 14.7(59) 1.0(4) 0.5(2) 8.1(65) 83.5(670)8.3(67) * 60 0.0(0) 18.3(11)73.3(44) 6.7(4) 1.7(1) 0.0(0) 10.0(3) 85.8(53) 4.2(4) *P<0.05 2.2 CHD E2 TC Lpa,ApoA HDL CHD,E4/E4 TC LDL Lpa,, 2 E3/E3,E2/ (P<0.05);
2 (P>0.05) ( )201710,57 5 2 CHD x±s E2/E2 E2/E3 E3/E3 E3/E4 E2/E4 E4/E4 TCc/(mmol L -1 ) 1.02±0.6 * 4.07±1.0 3.98±0.8 4.30±1.1 4.49±0.9 5.72±0.8 * 4.30±1.0 TGc/(mmol L -1 ) 1.29±0.4 1.73±1.7 0.88±0.4 1.43±1.0 0.52±0.7 1.33±0.2 1.48±1.1 HDLc/(mmol L -1 ) 1.50±0.2 * 1.12±0.4 1.11±0.2 1.16±0.3 1.09±0.2 1.19±0.1 1.15±0.3 LDLc/(mmol L -1 ) 2.1±0.7 2.24±0.7 2.39±0.8 2.63±0.8 2.81±0.8 4.08±0.2 * 2.60±0.8 ApoAρ /( g L -1 ) 1.39±0.1 * 1.17±0.2 1.05±0.1 1.24±0.2 1.22±0.1 1.22±0.3 1.21±0.2 ApoBρ /( g L -1 ) 0.61±0.2 1.90±5.6 0.88±0.2 0.91±0.2 0.97±0.2 1.40±0.0 0.92±0.2 Lpaρ /( mg L -1 ) 79.67±51.4 * 194.85±190.8410.66±248.7255.80±248.9301.66±29.1 606.50±14.9 * 257.06±249.1 *P<0.05E3/E3 3 CHD, TC LDL-C (E4/3>E3/, ApoE 3>E3/2,P <0.05) CHD 19,3579, 4 ApoE6,E3/E3, 3,ApoE 3 E2/E2 TC Lpa,HDL ApoA E2 E3E4, 6,3 (E2/E2 E3/E3 E4/E4)3 (P<0.05), ApoE [7] (E3/E4 E2/E3 E2/E4) ApoE β-vldl,apoe ApoE [15],, ApoE ;E4/E4 TC LDL Lpa, ApoE CHD,ApoE CHD ApoB LDH-C,,E4/E4 E3/E3 LDH-C,ApoB -ApoE,,ApoE [8] CHD ApoE LDH-C ApoB CHD [16],CHD ApoE ApoE, - ApoE -, ApoE [6] [17] e4 CHD LDH-C : CHD,ApoE E3/E3 e3,e2/e2 E4/E4 e2 e4, CHD,CHD e4,,apoe e4 CHD CHD [9-11] CHD, :, [1],. [J].,,2002,22(8):449-451. [12] [13],TC [2],,,. 5.2~5.7 mmol L -1 CHD [J].,2017,, CHD TC 25(2):171-174. [14] [3]. LPa [J].,2017,24(4):521-522., [4] MahoneySanchezL,BelaidiA A,BushAI,etal.Thecomplex ApoE roleofapolipoproteineinalzheimer'sdisease:anoverviewand, CM VLDL update[j].jmolneurosci,2016,60(3):325-335. ( 40)
40 ( )201710,57 5 Clin MonitComput,2012,26(2):75-83. T-Line Tensymetercontinuous noninvasive blood pressure [9],,,. deviceduringinducedhypotension[j].anaesthesia,2008,63 [J].,2016,37(1):24-26. (3):307-312. [10],,,. [17] Lin W Q,Wu H H,SuCS,etal.Comparisonofcontinuous [J].,2016(1):27-30. sessmentofthetechnology[j].cardiovascres,1998,38(3): 605-616. [14] NgK G,SmalCF.Surveyofautomatednoninvasiveblood pressuremonitors[j].jclineng,1994,19(6):452-475. [15] JaneleG M,GravensteinN.AnaccuracyevaluationoftheT- Line Tensymeter(continuous noninvasive blood pressure managementdevice)versusconventionalinvasiveradialartery monitoringinsurgicalpatients[j].anesth Analg,2006,102 (2):484-490. [16] SzmukP,PivalizzaE,WartersR D,etal.Anevaluationofthe noninvasivebloodpressuremonitoringbytl-300withstand- ardinvasivebloodpressuremeasurementinpatientsundergo- ingelectiveneurosurgery[j].jneurosurganesthesiol,2017, 29(1):1-7. [18] MeidertAS,HuberW,MulerJN,etal.Radialarteryappla- [12]. [J].,2016 (3):295-297. [13] ScheerB,PerelA,PfeiferUJ.Clinicalreview:complications nationtonometryforcontinuousnon-invasivearterialpres- sure monitoringinintensivecareunitpatients:comparison withinvasivelyassessedradialarterialpressure[j].brjan- MedEngTechnol,2013,37(3):197-202. [7] SaugelB,MeidertAS,HapfelmeierA,etal.Non-invasivecon- tinuousarterialpressure measurementbasedonradialartery tonometryintheintensivecare unit:a method comparison studyusingthet-linetl-200prodevice[j].brj Anaesth, 2013,111(2):185-190. [8] DueckR,GoedjeO,CloptonP.Noninvasivecontinuousbeat-to-beat radialarterypressureviatl-200applanationtonometry[j].j [11] ImholzB P,Wieling W,van MontfransG A,etal.Fifteen yearsexperiencewithfingerarterialpressuremonitoring:as- andriskfactorsofperipheralarterialcathetersusedforhae- modynamicmonitoringinanaesthesiaandintensivecaremedi- cine[j].critcare,2002,6(3):199-204. aesth,2014,112(3):521-528. ( : ) 櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐 ( 22) [5] NagahamaK,IsekiK,InoueT,etal.Hyperuricemiaandcardio- vascularriskfactorclusteringinascreenedcohortinokinawa, Japan[J].HypertensRes,2004,27(4):227-233. [6] Alderman M,AiyerKJ.Uricacid:roleincardiovasculardisease andefectsoflosartan[j].curr MedResOpin,2004,20(3): 369-379. [7] GranérM,KahriJ,VarpulaM,etal.ApolipoproteinEpolymor- phismisassociatedwithbothcarotidandcoronaryatherosclero- sisinpatientswithcoronaryarterydisease[j].nutrmetabcar- andcoronaryheartdiseasein56,000 whitesandblacks[j]. AmJHum Genet,2014,94(2):223-232. [12] YangSL,HeBX,Liu H L,etal.ApolipoproteinEgenepoly- morphismsandriskforcoronaryarterydiseaseinchinesexin- jianguygurandhanpopulation[j].chin MedSciJ,2004,19 (2):150-154. [13] MizunoK,NakayaN,OhashiY,etal.Usefulnessofpravastatinin primarypreventionofcardiovasculareventsinwomen:analysisof the ManagementofElevatedCholesterolinthePrimaryPre- diovascdis,2008,18(4):271-277. [8],,,. ApoE [J].,2004,8(21): 4194-4195. [9] MohanA V,FazelR,HuangP H,etal.Changesingeographic variationintheuseofpercutaneouscoronaryinterventionfor tion,2008,117(4):494-502. [14],. LP(a) [J].,2005,12(21):752-753. [15],,. E [J].,2011,8(18):2181-2182. stableischemicheartdiseaseafterpublicationofthe Clinical OutcomesUtilizingRevascularizationand AggressiveDrugE- valuation(courage)trial[j].circ Cardiovasc Qual Out- comes,2014,7(1):125-130. [10] AkinkuolieA O,PaynterNP,PadmanabhanL A.High-Densi- tylipoproteinparticlesubclassheterogeneityandincidentcor- onaryheartdisease[j].circcardiovascqualoutcomes,2014, 7(1):55-63. [11] PelosoG M,AuerPL,BisJC,etal.AssociationofLow-Fre- quencyandrare Coding-Sequencevariants withbloodlipids [16] WeggemansR M,ZockPL,OrdovasJM,etal.ApoproteinE genotypeandtheresponseofserumcholesteroltodietaryfat, cholesterolandcafestol[j].atherosclerosis,2001,154(3): 547-555. ventiongroupofadultjapanese(megastudy)[j].circula- [17] KobayashiJ,SaitoY,TairaK,etal.Efectofapolipoprotein E3/4phenotypeonpostprandialtriglyceridesandretinylpal- mitatemetabolisminplasmafrom hyperlipidemicsubjectsin Japan[J].Atherosclerosis,2001,154(3):539-546. ( : )
冠心病患者 ＡｐｏＥ 基因多态性及其脂质谱相关性研究 正文见第 ２０ 页 Ａ Ｅ２ Ｅ３ Ｂ Ｅ３ Ｅ３ Ｃ Ｅ４ Ｅ４ Ｄ Ｅ３ Ｅ４ 图 １ ＡｐｏＥ 基因芯片结果 经会阴超声在诊断盆腔脏器脱垂中的应用 正文见第 ５４ 页 １ 坐标轴为耻骨联合内下缘的水平线与耻骨联合中轴线 Ｘ 轴夹 角 ４５ ２ 静 息 期 张 力 期 缩 肛 期 三 种 不 同 状 态 下 ＢＮ ＶＤ 的测值 ３ 不同状态下 Ｃ ＶＤ 的测值 ４ 不同状态下 ＲＡ ＶＤ 的测值 图 １ 静息期 张力期 缩肛期超声声像图表现及 ＲＡ ＶＤ Ｃ ＶＤ ＢＮ ＶＤ 的测量 完全型 ｋａ ｒ ｔ ａ ｅｎｅ ｒ综合征 １ 例报告 正文见第 ９８ 页 ｇ Ａ 示右位心 Ｂ 脏器反位 Ｃ 左肺中叶不张及扩张支气管影 Ｄ 右肺下叶不张及扩张支气管影 Ｅ 鼻窦炎 Ｆ 支气管炎 图 １ 完全型 ＫＳ 的影像学表现